Biotech RadarJobs updated

COMPANY

Cerecin

HQ: Broomfield, CO source · cerecin.com ↗ · Mountain

Clinical Phase 3

Cerecin is a healthcare company. From company website Source · Oct 13, 2026

Keywords: healthcare Alzheimer Disease Alzheimer's Disease Infantile Spasm Migraine Age-Associated Memory Impairment Taste Profile Assessments Tricaprilin AC-1202 AC-1204 AC-OLE-01-VA AC-1204 mixed in water AC-1202 mixed in water

Profile checked Oct 10, 2026

22Trials (company is sponsor)

Timeline

  1. Trial start 3: Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study source ↗
  2. Trial start Phase 1: AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions source ↗
  3. Trial start 1: A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects source ↗
  4. Trial start III: A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension source ↗
  5. Trial start Phase 1: Tricaprilin Infantile Spasms Pilot Study source ↗
  6. Trial start Phase 1: Tricaprilin Liquid Formulation PK Study source ↗
  7. Trial start 2: Tricaprilin Phase 2 Pilot Study in Migraine source ↗
  8. Trial start Phase 1: Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production source ↗
  9. Trial start Phase 1: Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production source ↗
  10. Trial start Phase 1: Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides source ↗
  11. Trial start Phase 1: Taste-masking Study for Tricaprilin in Sensory Panelists source ↗
  12. Trial start Phase 1: Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production source ↗
  13. Trial start Phase 1: Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production source ↗
  14. Trial start Phase 1: Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production source ↗
  15. Trial start Phase 1: Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production source ↗
  16. Trial start Phase 1: Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production source ↗
  17. Trial start Phase 2/Phase 3: AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext source ↗
  18. Trial start —: Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease source ↗
  19. Trial start —: Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly source ↗
  20. Trial start Phase 2: Tricaprilin In Age-Associated Memory Impairment source ↗
  21. Trial start Phase 2: Tricaprilin in Mild to Moderate Alzheimer's Disease source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 22

RecordTitlePhaseStatusStartPrimary completion
NCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study3Not yet recruiting2026-122029-06 (estimated)
NCT04727970Tricaprilin Infantile Spasms Pilot StudyPhase 1CompletedNov 1, 2021Dec 4, 2023 (actual)
NCT04437199Tricaprilin Phase 2 Pilot Study in Migraine2CompletedDec 17, 2020Feb 7, 2022 (actual)
NCT05628636AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing ConditionsPhase 1CompletedNov 14, 2022Dec 22, 2022 (actual)
NCT05408780A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects1CompletedJul 14, 2022Aug 13, 2022 (actual)
NCT05028114Tricaprilin Liquid Formulation PK StudyPhase 1TerminatedAug 31, 2021Mar 18, 2022 (actual)
NCT04187547A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label ExtensionIIIWithdrawnJun 30, 2022Dec 31, 2023 (estimated)
NCT01741194AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label ExtPhase 2/Phase 3Completed2013-03Oct 24, 2016 (actual)
NCT00142805Tricaprilin in Mild to Moderate Alzheimer's DiseasePhase 2CompletedNov 4, 2004Jun 29, 2006 (actual)
NCT00355550Tricaprilin In Age-Associated Memory ImpairmentPhase 2Completed2006-072007-06 (actual)
NCT03971123Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body ProductionPhase 1CompletedAug 30, 2019Apr 2, 2020 (actual)
NCT04268953Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body ProductionPhase 1CompletedFeb 27, 2020Mar 26, 2020 (actual)
NCT03628352Taste-masking Study for Tricaprilin in Sensory PanelistsPhase 1CompletedSep 10, 2018Aug 22, 2019 (actual)
NCT03551769Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body ProductionPhase 1CompletedAug 5, 2018Aug 16, 2018 (actual)
NCT03635879Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain TriglyceridesPhase 1WithdrawnFeb 13, 2019Apr 16, 2019 (estimated)
NCT03063645Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body ProductionPhase 1CompletedMar 11, 2017Apr 7, 2017 (actual)
NCT02959710Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body ProductionPhase 1Completed2016-112017-02 (actual)
NCT02833012Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body ProductionPhase 1Completed2016-072016-09 (actual)
NCT02747602Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body ProductionPhase 1Completed2016-042016-05 (actual)
NCT01538212Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's DiseaseNot listedCompleted2012-012012-10 (actual)
NCT01211782AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)Phase 2/Phase 3WithdrawnNot listedNot listed
NCT00660088Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy ElderlyNot listedCompleted2008-042008-06 (actual)

Connect

Contact page

Feedback